BioCryst Pharmaceuticals Company Profile (NASDAQ:BCRX)

About BioCryst Pharmaceuticals (NASDAQ:BCRX)

BioCryst Pharmaceuticals logoBioCryst Pharmaceuticals, Inc. is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology. The Company's drug candidates include RAPIVAB, RAPIACTA, ALPIVAB, PERAMIFLU, Avoralstat, BCX7353, other second generation hereditary angioedema (HAE) compounds, Galidesivir and Forodesine. Its product RAPIVAB contains peramivir. ALPIVAB is an intravenous neuraminidase inhibitor. Galidesivir is a broad-spectrum antiviral (BSAV) research program developed for the treatment of hemorrhagic fever viruses. Forodesine is a Purine Nucleoside Phosphorylase (PNP) inhibitor in development by Mundipharma as a treatment for cancer.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:BCRX
  • CUSIP: 09058V10
  • Web: www.biocryst.com
Capitalization:
  • Market Cap: $386.05 million
  • Outstanding Shares: 80,428,000
Average Prices:
  • 50 Day Moving Avg: $5.25
  • 200 Day Moving Avg: $5.54
  • 52 Week Range: $3.75 - $9.25
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -6.15
  • P/E Growth: -0.34
Sales & Book Value:
  • Annual Revenue: $29.28 million
  • Price / Sales: 13.18
  • Book Value: $0.30 per share
  • Price / Book: 16.00
Profitability:
  • EBITDA: ($42,940,000.00)
  • Net Margins: -160.97%
  • Return on Equity: -276.62%
  • Return on Assets: -44.43%
Debt:
  • Debt-to-Equity Ratio: 0.94%
  • Current Ratio: 1.57%
  • Quick Ratio: 1.54%
Misc:
  • Average Volume: 1.55 million shs.
  • Beta: 3.37
  • Short Ratio: 17.05
 

Frequently Asked Questions for BioCryst Pharmaceuticals (NASDAQ:BCRX)

What is BioCryst Pharmaceuticals' stock symbol?

BioCryst Pharmaceuticals trades on the NASDAQ under the ticker symbol "BCRX."

How were BioCryst Pharmaceuticals' earnings last quarter?

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) released its quarterly earnings data on Monday, August, 7th. The company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.19) by $0.02. The business had revenue of $3.10 million for the quarter, compared to analysts' expectations of $5.79 million. BioCryst Pharmaceuticals had a negative net margin of 160.97% and a negative return on equity of 276.62%. The company's quarterly revenue was down 35.4% on a year-over-year basis. During the same period last year, the business earned ($0.22) earnings per share. View BioCryst Pharmaceuticals' Earnings History.

When will BioCryst Pharmaceuticals make its next earnings announcement?

BioCryst Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, November, 6th 2017. View Earnings Estimates for BioCryst Pharmaceuticals.

Where is BioCryst Pharmaceuticals' stock going? Where will BioCryst Pharmaceuticals' stock price be in 2017?

10 brokers have issued 1 year price objectives for BioCryst Pharmaceuticals' shares. Their forecasts range from $6.00 to $15.00. On average, they anticipate BioCryst Pharmaceuticals' stock price to reach $9.25 in the next twelve months. View Analyst Ratings for BioCryst Pharmaceuticals.

What are analysts saying about BioCryst Pharmaceuticals stock?

Here are some recent quotes from research analysts about BioCryst Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallography and structure-based drug design for the development of novel therapeutics to treat cancer, cardiovascular diseases, autoimmune diseases, and viral infections. The company is advancing multiple internal programs toward potential commercialization including Fodosine in oncology, BCX-4208 in transplantation and autoimmune diseases and peramivir in seasonal and life threatening influenza. BioCryst has a worldwide partnership with Roche for the development and commercialization BCX-4208, and is collaborating with Mundipharma for the development and commercialization of Fodosine in markets across Europe, Asia, Australia and certain neighboring countries. " (8/10/2017)
  • 2. Needham & Company LLC analysts commented, "Shire (SHPG) reported positive results from the ph 3 HELP trial evaluating lanadelumab (fka SHP643) as a prophylactic HAE treatment. Lanadelumab, an antibody that binds and inhibits plasma kallikrein, is formulated for subcutaneous administration and has a long half-life (~14 days) that enables once- or twice-monthly dosing. The HELP trial met all of its endpoints; monthly attack rate reduction vs. placebo for all dosing regimens ranged from 73% – 87% (p<0.001). A BLA filing for lanadelumab is expected in late-2017/early-2018. BCRX's BCX7353, a daily orally-administered HAE prophylactic candidate, is currently under evaluation in the ph 2 APeX-1 trial. Positive interim results reported in late-Feb showed that BCX7353 led to a ~52% HAE attack rate reduction (p=0.035, ITT), with results showing a dichotomy of efficacy between peripheral attacks (~88% reduction) and abdominal attacks (~24% reduction). Additional APeX-1 cohorts evaluating lower-doses of BCX7353 are expected to report in 2Q17. These data should provide clarity on the efficacy/tolerability profile of BCX7353 and help shed some light on its potential role in HAE prophylaxis."" (5/19/2017)

Are investors shorting BioCryst Pharmaceuticals?

BioCryst Pharmaceuticals saw a decrease in short interest in the month of September. As of September 29th, there was short interest totalling 10,746,206 shares, a decrease of 25.1% from the September 15th total of 14,348,677 shares. Based on an average daily trading volume, of 2,214,130 shares, the days-to-cover ratio is currently 4.9 days. Approximately 11.1% of the company's stock are sold short.

Who are some of BioCryst Pharmaceuticals' key competitors?

Who are BioCryst Pharmaceuticals' key executives?

BioCryst Pharmaceuticals' management team includes the folowing people:

  • Robert A. Ingram, Chairman of the Board
  • Jon P. Stonehouse, President, Chief Executive Officer, Director
  • Thomas R. Staab II, Chief Financial Officer, Senior Vice President, Principal Accounting Officer, Treasurer
  • Yarlagadda S. Babu Ph.D., Senior Vice President - Drug Discovery
  • Lynne M Powell, Senior Vice President, Chief Commercial Officer
  • William P. Sheridan, Senior Vice President, Chief Medical Officer
  • Alane P. Barnes, Vice President, General Counsel, and Corporate Secretary
  • Fred E. Cohen Ph.D. M.D., Director
  • Sanj K. Patel, Director
  • George B. Abercrombie, Independent Director

How do I buy BioCryst Pharmaceuticals stock?

Shares of BioCryst Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is BioCryst Pharmaceuticals' stock price today?

One share of BioCryst Pharmaceuticals stock can currently be purchased for approximately $4.80.


MarketBeat Community Rating for BioCryst Pharmaceuticals (NASDAQ BCRX)
Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  251 (Vote Outperform)
Underperform Votes:  217 (Vote Underperform)
Total Votes:  468
MarketBeat's community ratings are surveys of what our community members think about BioCryst Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for BioCryst Pharmaceuticals (NASDAQ:BCRX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Hold Ratings, 7 Buy Ratings
Consensus Rating:Buy (Score: 2.70)
Consensus Price Target: $9.25 (92.71% upside)
Consensus Price Target History for BioCryst Pharmaceuticals (NASDAQ:BCRX)
Price Target History for BioCryst Pharmaceuticals (NASDAQ:BCRX)
Analysts' Ratings History for BioCryst Pharmaceuticals (NASDAQ:BCRX)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/14/2017Royal Bank Of CanadaInitiated CoverageSector Perform -> Sector Perform$6.00LowView Rating Details
9/6/2017HC WainwrightReiterated RatingBuy$10.00HighView Rating Details
9/6/2017J P Morgan Chase & CoBoost Price TargetOverweight -> Neutral$4.93 -> $9.00HighView Rating Details
9/6/2017Jefferies Group LLCUpgradeHold -> Buy$5.00 -> $7.00HighView Rating Details
9/5/2017Piper Jaffray CompaniesReiterated RatingOverweight$13.00 -> $15.00HighView Rating Details
8/8/2017Noble FinancialReiterated RatingBuyLowView Rating Details
5/19/2017Needham & Company LLCReiterated RatingHoldMediumView Rating Details
2/16/2017Ladenburg Thalmann Financial ServicesInitiated CoverageBuy$11.00N/AView Rating Details
1/23/2017FBR & CoReiterated RatingOutperformN/AView Rating Details
12/16/2016JMP SecuritiesUpgradeMarket Perform -> Outperform$10.00N/AView Rating Details
2/9/2016Rodman & RenshawLower Price TargetBuy$24.00 -> $10.00N/AView Rating Details
11/11/2015Bank of America CorporationDowngradeNeutral -> Underperform$12.00 -> $10.00N/AView Rating Details
11/10/2015Oppenheimer Holdings, Inc.Reiterated RatingMarket PerformN/AView Rating Details
(Data available from 10/23/2015 forward)

Earnings

Earnings History for BioCryst Pharmaceuticals (NASDAQ:BCRX)
Earnings by Quarter for BioCryst Pharmaceuticals (NASDAQ:BCRX)
Earnings History by Quarter for BioCryst Pharmaceuticals (NASDAQ BCRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/6/2017($0.18)N/AView Earnings Details
8/7/2017Q2 2017($0.19)($0.21)$5.79 million$3.10 millionViewListenView Earnings Details
5/4/2017Q1 2017($0.20)($0.19)$6.13 million$9.40 millionViewListenView Earnings Details
2/27/2017Q416($0.23)($0.06)$4.13 million$9.00 millionViewListenView Earnings Details
11/7/2016Q316($0.24)($0.16)$5.94 million$7.80 millionViewListenView Earnings Details
8/4/2016Q216($0.26)($0.22)$3.92 million$4.80 millionViewN/AView Earnings Details
5/5/2016Q116($0.23)($0.31)$5.42 million$4.82 millionViewN/AView Earnings Details
2/23/2016Q415($0.26)($0.25)$6.34 million$4.60 millionViewListenView Earnings Details
11/5/2015Q315($0.20)($0.20)$6.77 million$11.00 millionViewListenView Earnings Details
8/7/2015Q215($0.22)$0.06$7.10 million$25.80 millionViewListenView Earnings Details
5/8/2015Q115($0.24)($0.21)$4.30 million$6.80 millionViewListenView Earnings Details
2/18/2015Q414($0.20)($0.16)$3.64 million$5.40 millionViewListenView Earnings Details
11/6/2014Q314($0.20)($0.12)$2.11 million$3.20 millionViewListenView Earnings Details
8/5/2014Q214($0.19)($0.23)$2.32 million$1.50 millionViewN/AView Earnings Details
5/8/2014Q114($0.16)($0.17)$3.34 million$3.50 millionViewN/AView Earnings Details
2/26/2014Q413($0.08)($0.09)$8.81 million$10.60 millionViewN/AView Earnings Details
11/5/2013Q313($0.14)($0.14)$2.01 million$2.40 millionViewN/AView Earnings Details
8/8/2013Q2 2013($0.14)($0.23)$2.01 million$0.82 millionViewN/AView Earnings Details
5/7/2013Q1 2013($0.15)($0.09)$1.31 million$3.60 millionViewN/AView Earnings Details
2/19/2013Q4 2012($0.16)($0.22)$4.02 million$4.10 millionViewN/AView Earnings Details
11/8/2012Q312($0.22)($0.19)$4.63 million$5.80 millionViewN/AView Earnings Details
8/2/2012($0.26)($0.25)ViewN/AView Earnings Details
5/7/2012($0.26)($0.13)ViewN/AView Earnings Details
2/16/2012($0.33)($0.29)ViewN/AView Earnings Details
11/2/2011($0.30)($0.32)ViewN/AView Earnings Details
8/4/2011($0.26)($0.36)ViewN/AView Earnings Details
5/4/2011($0.20)($0.29)ViewN/AView Earnings Details
2/10/2011($0.21)($0.20)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for BioCryst Pharmaceuticals (NASDAQ:BCRX)
2017 EPS Consensus Estimate: ($0.56)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.14)($0.14)($0.14)
Q2 20171($0.17)($0.17)($0.17)
Q3 20171($0.13)($0.13)($0.13)
Q4 20171($0.12)($0.12)($0.12)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for BioCryst Pharmaceuticals (NASDAQ:BCRX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for BioCryst Pharmaceuticals (NASDAQ:BCRX)
Insider Ownership Percentage: 5.80%
Institutional Ownership Percentage: 70.21%
Insider Trades by Quarter for BioCryst Pharmaceuticals (NASDAQ:BCRX)
Institutional Ownership by Quarter for BioCryst Pharmaceuticals (NASDAQ:BCRX)
Insider Trades by Quarter for BioCryst Pharmaceuticals (NASDAQ:BCRX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/18/2017Fred E CohenDirectorSell54,250$5.42$294,035.00View SEC Filing  
3/20/2017Thomas R Staab IICFOSell3,250$9.20$29,900.00View SEC Filing  
3/10/2017Thomas R Staab IIInsiderSell3,250$9.06$29,445.00View SEC Filing  
3/8/2017Thomas R Staab IIInsiderSell6,500$8.43$54,795.00View SEC Filing  
3/6/2017Thomas R Staab IIInsiderSell3,250$7.90$25,675.00View SEC Filing  
12/19/2016Thomas R Staab IIInsiderSell3,250$7.45$24,212.50View SEC Filing  
9/14/2016Alane P BarnesVPSell8,357$4.27$35,684.39View SEC Filing  
8/25/2016Yarlagadda S BabuVPSell30,000$4.06$121,800.00View SEC Filing  
8/16/2016Bros. Advisors Lp BakerMajor ShareholderSell4,046,590$5.00$20,232,950.00View SEC Filing  
8/12/2016Thomas R Staab IIInsiderSell5,864$5.18$30,375.52View SEC Filing  
8/9/2016Thomas R Staab IIInsiderSell14,577$4.43$64,576.11View SEC Filing  
1/28/2016Bros. Advisors Lp Bakermajor shareholderBuy88,345$6.95$613,997.75View SEC Filing  
1/22/2016Bros. Advisors Lp Bakermajor shareholderBuy106,800$7.28$777,504.00View SEC Filing  
1/20/2016Bros. Advisors Lp Bakermajor shareholderBuy52,695$6.87$362,014.65View SEC Filing  
1/19/2016Bros. Advisors Lp Bakermajor shareholderBuy92,200$7.12$656,464.00View SEC Filing  
1/15/2016Bros. Advisors Lp Bakermajor shareholderBuy200,000$7.46$1,492,000.00View SEC Filing  
12/21/2015Thomas R Staab IICFOSell3,052$10.86$33,144.72View SEC Filing  
12/17/2015Thomas R Staab IICFOSell3,000$10.49$31,470.00View SEC Filing  
7/20/2015Thomas R Staab IICFOSell3,500$16.50$57,750.00View SEC Filing  
6/22/2015Thomas R Staab IICFOSell3,750$16.00$60,000.00View SEC Filing  
6/19/2015Alane P BarnesVPSell3,000$15.00$45,000.00View SEC Filing  
6/19/2015Jon P StonehouseCEOSell20,000$15.02$300,400.00View SEC Filing  
6/19/2015Thomas R Staab IICFOSell16,375$14.36$235,145.00View SEC Filing  
6/19/2015William P SheridanCMOSell70,389$15.05$1,059,354.45View SEC Filing  
6/5/2015Thomas R Staab IICFOSell6,000$12.75$76,500.00View SEC Filing  
5/18/2015Thomas R Staab IICFOSell3,000$11.00$33,000.00View SEC Filing  
3/19/2015Yarlagadda S BabuVPSell12,105$10.16$122,986.80View SEC Filing  
3/5/2015Yarlagadda S BabuVPSell37,400$10.59$396,066.00View SEC Filing  
3/4/2015Yarlagadda S BabuVPSell10,495$10.50$110,197.50View SEC Filing  
2/20/2015Nancy J HutsonDirectorBuy10,000$10.27$102,700.00View SEC Filing  
12/30/2014William P SheridanCMOSell128,399$12.36$1,587,011.64View SEC Filing  
12/29/2014Thomas R Staab IICFOSell9,500$12.56$119,320.00View SEC Filing  
12/29/2014William P SheridanCMOSell105,295$12.43$1,308,816.85View SEC Filing  
8/27/2014Thomas R Staab IICFOSell10,000$13.58$135,800.00View SEC Filing  
7/1/2014Thomas R Staab IICFOSell3,125$13.00$40,625.00View SEC Filing  
6/23/2014Thomas R Staab IICFOSell3,125$12.49$39,031.25View SEC Filing  
6/17/2014Thomas R Staab IICFOSell3,125$12.00$37,500.00View SEC Filing  
3/14/2014Thomas Staab IICFOSell3,125$11.24$35,125.00View SEC Filing  
3/6/2014Kenneth Lee, Jr.DirectorSell12,665$12.69$160,718.85View SEC Filing  
11/12/2013George AbercrombieDirectorBuy3,000$6.19$18,570.00View SEC Filing  
8/1/2013Felix BakerMajor ShareholderBuy1,136,364$4.40$5,000,001.60View SEC Filing  
3/5/2013George B AbercrombieDirectorBuy3,000$1.23$3,690.00View SEC Filing  
12/14/2012Peder JensenDirectorBuy20,000$1.51$30,200.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for BioCryst Pharmaceuticals (NASDAQ:BCRX)
Latest Headlines for BioCryst Pharmaceuticals (NASDAQ:BCRX)
Source:
Loading headlines, please wait.

Social

Chart

BioCryst Pharmaceuticals (BCRX) Chart for Monday, October, 23, 2017

This page was last updated on 10/23/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.